• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn . Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular

tetano

Editor, Senior Moderator
J Biomol Struct Dyn


. 2020 Jul 31;1-16.
doi: 10.1080/07391102.2020.1800514. Online ahead of print.
Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations


Nizar A Al-Shar'i[SUP] 1 [/SUP]



Affiliations

Abstract

The widespread of the COVID-19 disease, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), had severely affected the entire world. Unfortunately, no successful vaccines or antiviral drugs are currently available which leaves the scientific community under huge pressure to tackle this pandemic. Among the identified promising druggable targets, specific to this virus, is the main protease (M[SUP]pro[/SUP]) enzyme, which is vital for viral replication, transcription and packaging within the host cells. In this study, selective inhibition of the M[SUP]pro[/SUP] was sought via thorough analysis of its available structural data in the Protein Data Bank. To this end, COVID-19 M[SUP]pro[/SUP] crystal complexes were explored and the key interacting residues (KIRs) within its active site, that are expected to be vital for effective ligand binding, were identified. Based on these KIRs, 3D pharmacophore models were generated and used in virtual screening of different databases. Retrieved hits were docked into the active site of the enzyme and their MM-PBSA based free binding energies were calculated. Finally, ADMET descriptors were calculated to aid the selection of top scoring hits with best ADMET properties. Nine compounds with different chemotypes were identified as potential M[SUP]pro[/SUP] inhibitors. Further, MD simulations of a virtual complex of M[SUP]pro[/SUP] with one of the promising hits revealed stable binding which is indicative of good inhibitory potential. The identified compounds in this study are expected to support the global drug discovery efforts in fighting against this highly contagious virus by narrowing the searchable chemical space for potential effective therapeutics. Communicated by Ramaswamy H. Sarma.

Keywords: COVID-19; docking; key interacting residues; main protease; pharmacophore modeling.
 
Back
Top Bottom